| 366 | 1 | 85 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探讨短程大剂量阿托伐他汀对于动脉粥样硬化(AS)斑块的干预机制。方法:选择4周龄雄性apoE-/-小鼠高脂喂养6周建立AS模型,随机分为对照组、模型组、阿托伐他汀药物常规剂量组、中剂量组和高剂量组(负荷剂量组和非负荷剂量组)。2周后比较各组血脂水平、炎症因子浓度、血小板数目、血小板膜蛋白表达水平及斑块面积。结果:与模型组相比,对照组和阿托伐他汀药物各干预组HDL-C均显著增高,LDL-C均显著降低,血清及斑块内炎症因子水平明显下降,PLT均明显减少,CD31与CD62P荧光强度均显著降低(均P<0.05);负荷剂量组ox-LDL水平明显低于模型组(P<0.05)。阿托伐他汀药物各干预组斑块面积较模型组明显减小(均P<0.05)。结论:短程大剂量阿托伐他汀可能通过降低血脂水平,抑制相关炎症因子释放,调节血小板数目及血小板膜蛋白的表达来干预AS。
Abstract：Objective:To explore the intervention mechanism of short-term high-dose atorvastatin on atherosclerotic(AS)plaque.Methods:Four-week-old male apoE-/-mice were fed with high-fat diet for 6 weeks to induce AS.They were randomly divided into the control group,the model group,the atorvastatin conventional dose group,medium dose group and high dose group(loading dose group and non-loading dose group).The blood lipid levels,the concentration of inflammatory factors,the number of platelets,the expression level of platelet membrane protein and plaque area were analyzed at 2 weeks after treatment.Results:Compared with the model group,HDL-C was significantly increased,while LDL-C,serum and plaque inflammatory factors,PLT,CD31 and CD62 Pfluorescence intensity were all obviously decreased both in the control group and the atorvastatin intervention groups(all P <0.05).The level of ox-LDL in the loading dose of atorvastatin group was lower than that of model group(P<0.05).The plaque area in these atorvastatin intervention groups were significantly decreased than that of model group(all P <0.05).Conclusion:high-dose atorvastatin in short-term may interfere with AS by reducing blood lipid,inhibiting inflammatory factors,and regulating the number of platelets as well as the expression of platelet membrane proteins.
[1]Bondonno C P,Blekkenhorst L C,Prince R L,et al.Association of vegetable nitrate intake with carotid atherosclerosis and ischemic cerebrovascular disease in older women[J].Stroke,2017,48(7):1724-1729．
[2]Ndrepepa G,Colleran R,Kastrati A.Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease[J].Clin Chim Acta,2018,476:130-138．
[3]LaRosa J C,Grundy S M,Waters D D,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352(14):1425-1435．
[4]Mancini G,Martins W C,de Oliveira J,et al.Atorvastatin improves mitochondrial function and prevents oxidative stress in Hippocampus following amyloid-β1-40intracerebroventricular administration in mice[J].Mol Neurobiol,2020,57(10):4187-4201．
[5]Yang X,Xiong T,Ning D,et al.Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity[J].Toxicol Appl Pharmacol,2020,402:115132．
[6]Guo H Y,Xu F K,Lv H T,et al.Hyperhomocysteinemia independently causes and promotes atherosclerosis in LDL receptor-deficient mice[J].J Geriatr Cardiol,2014,11(1):74-78．
[7]丁虹．实验药理学[M]．北京：科学出版社，2008:13-16．
[8]Li X X,Xiao H,Lin C W,et al.Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis[J].Int J Nanomed,2019,14:649-665．
[9]Coutinho J M,Middeldorp S,Stam J.Advances in the treatment of cerebral venous thrombosis[J].Curr Treat Options Neurol,2014,16(7):299．
[10]Sun B,Rui R P,Pan H Y,et al.Effect of combined use of astragaloside IV (AsIV)and atorvastatin (AV)on expression of PPAR-γand inflammation-associated cytokines in atherosclerosis rats[J].Med Sci Monit,2018,24:6229-6236．
[11]Cao B,Bi G,Wang Y.Pharmacology of atorvastatin on myocardial ischemia-reperfusion in rats and drug effect analysis[J].Pak J Pharm Sci,2019,32(5(special)):2443-2447．
[12]Zhu Z S,Li J Y,Zhang X R.Astragaloside IV protects against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury by reducing oxidative stress and inflammation[J].Med Sci Monit,2019,25:2132-2140．
[13]Cai L,Zhang X,Hou M,et al.Natural flavone tricetin suppresses oxidized LDL-induced endothelial inflammation mediated by Egr-1[J].Int Immunopharmacol,2020,80:106224．
[14]Wolf D,Ley K.Immunity and Inflammation in Atherosclerosis[J].Circ Res.2019,124(2):315-327．
[15]Abela O G,Ahsan C H,Alreefi F,et al.Plaque rupture and thrombosis:the value of the atherosclerotic rabbit model in defining the mechanism[J].Curr Atheroscler Rep,2016,18(6):29．
[16]Wang X,Cai X,Chen L,et al.The evaluation of plasma and leukocytic IL-37expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI[J].Mediators Inflamm,2015,2015:626934．
[17]Shadab M,Millar M W,Slavin S A,et al.Autophagy protein ATG7is a critical regulator of endothelial cell inflammation and permeability[J].Sci Rep,2020,10(1):13708．
[18]Badimon L,Vilahur G.Thrombosis formation on atherosclerotic lesions and plaque rupture[J].J Intern Med.2014,276(6):618-632．
[19]谭朝阳，刘大伟，殷建．氯吡格雷联合阿托伐他汀对急性心肌梗死患者血小板和血液流变学及D-Dimer和hs-CRP的影响[J]．遵义医学院学报，2017,40(1):68-71．
[20]Deng Y,Zou W,Chen G,et al.Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease[J].Int J Neurosci,2019,129(11):1133-1138．
[21]Bot I,Jukema J W,Lankhuizen I M,et al.Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels[J].Atherosclerosis,2011,214(2):295-300.
基本信息:
中图分类号:R965
引用信息:
[1]杨伟,贺超,张再强,等.短程大剂量阿托伐他汀对apoE~(-/-)小鼠动脉粥样硬化模型的作用[J].巴楚医学,2021,4(03):60-64.
基金信息:
国家自然科学基金项目（No:81770456）; 宜昌市医疗卫生科研项目（No:A17-301-05）
2021-09-30
2021-09-30